Special Issue "The Use of Nanoparticles in Vaccine Development"
Deadline for manuscript submissions: 31 August 2024 | Viewed by 113
Interests: T cells; viral infections; bacterial infections; vaccine delivery; animal vaccine models
Vaccines have been a cornerstone of public health, successfully controlling and eradicating infectious diseases around the world. However, despite their effectiveness, certain challenges persist, including weak immunogenicity, in vivo instability, toxicity concerns, and the need for multiple administrations. Recent advancements in nanotechnology offer potential solutions to address these limitations and revolutionize vaccine development.
Potential topics for this Special Issue may include, but are not limited to, the following:
- The design and engineering of nanoparticle-based vaccine delivery systems;
- Immune responses elicited by nanoparticle vaccines;
- Novel adjuvants and formulations using nanoparticles;
- The biocompatibility and safety assessment of nanoparticle vaccines;
- Nanoparticles used for targeted vaccine delivery and enhanced antigen presentation;
- The stability and storage of nanoparticle-based vaccines;
- Clinical trials and translational studies of nanoparticle vaccines;
- The comparative analysis of nanoparticle vaccines with conventional vaccine approaches;
- Nanoparticles in the development of vaccines against emerging infectious diseases.
This Special Issue aims to collate leading experts, researchers, and practitioners from diverse disciplines to explore and share their findings related to nanoparticle-based vaccine strategies. We envision a collection of high-quality original research articles, reviews, and perspectives that will provide valuable insights into the application of nanoparticles in vaccine development.
Dr. Seyed Davoud Jazayeri
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- vaccine development
- infectious diseases
- innate immune response
- adaptive immune response
- animal model study